Search

Your search keyword '"YUEN, M. F."' showing total 508 results

Search Constraints

Start Over You searched for: Author "YUEN, M. F." Remove constraint Author: "YUEN, M. F."
508 results on '"YUEN, M. F."'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

2. High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy

4. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

9. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

10. Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors.

11. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation

12. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy

13. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

14. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B:An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

15. Global multi-stakeholder endorsement of the MAFLD definition

16. Strategies to manage hepatitis C virus infection disease burden—Volume 4

17. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm: Volume 4

18. Historical epidemiology of hepatitis C virus in select countries—volume 4

21. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

22. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

23. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

27. The case for simplifying and using absolute targets for viral hepatitis elimination goals

28. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

29. Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment.

30. The pharmacokinetic and safety profiles of ro7445482 sirna are similar between asian and nonasian healthy volunteers and chronic hepatitis b patients in a phase 1 study.

32. Risk of hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels

33. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.

34. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

35. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

37. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. (Helicobacter Pylori)

38. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. (Hepatitis)

44. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

Catalog

Books, media, physical & digital resources